These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8182001)

  • 21. Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity.
    Razzaque MS; Hossain MA; Ahsan N; Taguchi T
    Nephron; 2001 Nov; 89(3):251-4. PubMed ID: 11598385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Amphotericin B: the end of an era].
    Oude Lashof AM; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New aspects in treatment of systemic mycoses].
    Presterl E; Graninger W
    Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions.
    Nicholl TA; Nimmo CR; Shepherd JD; Phillips P; Jewesson PJ
    Ann Pharmacother; 1995 Nov; 29(11):1081-7. PubMed ID: 8573948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.
    Eriksson U; Seifert B; Schaffner A
    BMJ; 2001 Mar; 322(7286):579-82. PubMed ID: 11238151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients.
    Hall P; Kennedy G; Morton J; Hill GR; Durrant S
    Intern Med J; 2005 Jun; 35(6):374. PubMed ID: 15892774
    [No Abstract]   [Full Text] [Related]  

  • 28. Retrospective review of amphotericin B use in a tertiary-care medical center.
    Gross MH; Pickard WW; Perfect JR
    Am J Hosp Pharm; 1987 Jun; 44(6):1353-7. PubMed ID: 3618612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amphotericin B lipid complex.
    Rapp RP; Gubbins PO; Evans ME
    Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal amphotericin B: what is its role in 2008?
    Lanternier F; Lortholary O
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
    Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
    Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
    Azanza Perea JR; Barberán J
    Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug therapy of intractable mycoses].
    Ikemoto H
    Nihon Naika Gakkai Zasshi; 1990 Dec; 79(12):1680-4. PubMed ID: 2079591
    [No Abstract]   [Full Text] [Related]  

  • 34. Rapid infusion of amphotericin B: is it safe, effective, and wise?
    Schuler U; Ehninger G
    Am J Med; 1995 Jul; 99(1):104-5. PubMed ID: 7598128
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical efficacies of antifungal injections].
    Fujii Y; Inase N; Yoshizawa Y
    Nihon Rinsho; 2008 Dec; 66(12):2378-83. PubMed ID: 19069109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
    Loo AS; Muhsin SA; Walsh TJ
    Expert Opin Drug Saf; 2013 Nov; 12(6):881-95. PubMed ID: 23931455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
    Groll AH; Müller FM; Piscitelli SC; Walsh TJ
    Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of nephrotoxicity with the administration of amphotericin B in a lipid emulsion.
    Smith TM; Strozyk WR
    Ann Pharmacother; 1994 Nov; 28(11):1307-8. PubMed ID: 7849357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.